Business
Pacira BioSciences Announces Notice of Allowance of New Patent for EXPAREL
Composition claims for EXPAREL 200-liter process extend patent protection into 2041 PARSIPPANY, N.J., May 18, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences,
About this update from Pacira Biosciences, Inc.
[{"type":"text","content":"Composition claims for EXPAREL 200-liter process extend patent protection into 2041\nPARSIPPANY, N.J., May 18, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 17/156,400 related to EXPAREL® (bupivacaine liposome injectable suspension). The allowed application, “Manufacturing of Bupivacaine Multivesicular Liposomes” claims composition of EXPAREL prepared by the company’s 200-liter commercial-scale manufacturing process. A Notice of Allowance is issued after the USPTO determines that the prosecution on the merits of a patent has been completed. The USPTO then grants the patent upon payment of the patent issuance fee. The new patent will have an expiration date of January 22, 2041. “This new patent marks the first deliverable from our comprehensive patent strategy and adds yet another layer of market exclusivity that extends our proprietary position for EXPAREL into the 2040s,” said Dave Stack, chairman and chief executive officer of Pacira BioSciences. “The comprehensive nature of the allowed claims underscores the deep multivesicular liposome manufacturing expertise that Pacira has accumulated over more than 25 years. Over the last six years, we have invested more than $100 million to create, design and commercialize a more efficient method for making EXPAREL, exceeding the U.S. Food and Drug Administration’s (FDA) rigorous standards for safety and bioequivalence. Our innovative manufacturing processes for EXPAREL are a core competency that we are committed to safeguarding globally.” “Our growing intellectual property portfolio provides significant barriers of entry, protects us from would be competitors, and gives us confidence in long-term market leadership for EXPAREL as the only non-opioid, single-dose, long-acting local analgesic that is FDA-approved for infiltration, field block and brachial plexus nerve block,” continued Mr. Stack. Pacira intends to submit the patent for listing in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book) after securing FDA approval of its 200-liter manufacturing process. The FDA is current...